TScan Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc. (TCRX) on January 24, 2024, with the earliest event reported on that date. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $500,000 per annum.
- One-Time Payment: $60,000.
- Equity Grant: Option to purchase 750,000 shares of voting common stock.
- Exercise Price: Fair market value on February 1, 2024.
- Discretionary Bonus: Target up to 40% of base salary.
Material Changes
Effective January 29, 2024, Jason A. Amello was appointed as Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer. This appointment ends the interim roles previously held by CEO Gavin MacBeath (interim principal financial officer) and VP of Finance Leiden Dworak (principal accounting officer and Treasurer).
Outlook, Risks, and Unusual Items
The filing details severance and change of control provisions:
- Change in Control: If terminated without cause or resigns for good reason within 3 months before or 12 months after a change in control, Mr. Amello is entitled to 1x base salary plus target bonus, pro-rata bonus, immediate acceleration of unvested equity, and up to 12 months of COBRA premiums.
- Standard Termination: If terminated without cause or resigns for good reason outside of a change in control, Mr. Amello is entitled to 12 months of base salary and up to 12 months of COBRA premiums.
The filing notes that the complete Employment Agreement will be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2024.
Investor Verification Checklist
- Verify the fair market value of the stock on February 1, 2024, to determine the exercise price of the 750,000 share option.
- Review the full Employment Agreement in the upcoming Form 10-Q for detailed definitions of "without cause," "good reason," and "change in control."
- Monitor the vesting schedule: 25% vests after 12 months, with the remainder vesting in 36 equal monthly installments.
- Confirm the impact of the new CFO appointment on the company's financial reporting and strategic direction.